Observational study

Key findings of the study

Adverse effects were minimal and included (transient) symptom exacerbation, paraesthesia or headache. The study strictly adhered to best clinical practices and was closely monitored.

  • Following 4 weeks of treatment, both fatigue levels (FSS) and quality of life (WHO-Quol-5) showed statistically significant improvements.
  • With a large effect size (Cohen’s d over 0.7), the therapy demonstrated a clinically significant effect.
  • The patients treated solely with the RIFETECH® device reported significant improvements.
  • The medical practitioners described the therapy as a complete success for 64.5 % of the patients, while 28.2 % of the patients were considered to have partially recovered.